Exosome Therapy for Pattern Hair Loss: Ersan 2024 Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in Aesthetic Plastic Surgery, 2024
Exosome Therapy for Pattern Hair Loss: Ersan 2024 Research Summary
Study conclusion
No randomised controlled trial evidence for exosome therapy for hair loss exists as of 2025. This prospective study of 30 patients reported improvements in hair density and thickness after exosome treatment. However, the study had no control or placebo group, making it impossible to determine whether the improvement was caused by the treatment or would have occurred without it.
Strength of evidence
Who it applies to
Who was studied
30 patients with androgenetic alopecia (pattern hair loss). Non-randomised — no control or placebo group.
Who was NOT studied
Anyone outside this small group of 30 patients. No comparison to placebo, minoxidil, or other treatments was made.
What to look for when shopping
Exosome therapy is a clinic-based experimental procedure. It is not FDA-approved for hair loss. The FDA has issued warnings about unapproved exosome products due to safety concerns. No peer-reviewed randomised controlled trial evidence supports its use for hair loss as of 2025.
What research cannot help you decide
Whether exosome therapy actually causes hair growth — without a control group, this study cannot answer that question. How exosome therapy compares to any other treatment. Whether it is safe.
Key findings
- Improvements in hair density and thickness were reported in 30 patients after exosome treatment
- The study had no control or placebo group — it cannot determine whether treatment caused the improvement
- No randomised controlled trial of exosome therapy for hair loss has been published as of 2025
- Exosome therapy is not FDA-approved for hair loss
- The FDA has issued warnings about unapproved exosome products due to safety concerns
What this study does not show
- 1.Whether exosome therapy causes hair growth — without a control group, this study cannot answer that question.
- 2.How exosome therapy compares to any other treatment.
- 3.Whether it is safe — no controlled safety data exists.
- 4.Which exosome source, preparation, or injection protocol is optimal.
Limitations
- 1.No control group or placebo group — the most serious limitation. Results cannot be attributed to the treatment.
- 2.Only 30 patients — an extremely small sample.
- 3.Non-randomised prospective design — the weakest clinical study design for assessing treatment effectiveness.
- 4.Exosome therapy is not FDA-approved for hair loss. The FDA has issued warnings about unapproved exosome products.
- 5.No independent replication of these findings exists.
Used in these articles
Links added as fact-checks and articles citing this study are published.